References
- 1. Fukazawa K, Lee HT. Volatile anesthetics and AKI: risk, mechanisms, and a potential therapeutic window. J Am Soc Nephrol, 2014;25:884-892.
- 2. Lee HC, Kim D, Ahn W, Sim J, Chung Y. Comparison of the renal safety between carbon dioxide absorbent products under sevoflurane anesthesia: a pilot study. Korean J Anesthesiol, 2012;63:11–17.
- 3. Stoian M, Stoian Adina, Cozma D, et al. Modification of Renal Permeability for Proteins after General Anesthesia with Sevoflurane and Desfluran. Acta Medica Marisiensis, 2011;57 (suppl 3):23-24.
- 4. Stoian M, Stoian A, Onisor D, Brusnic O, Cozma D, Buicu F. Urine protein separation by geometrical electrophoresis after anaesthesia with sevoflurane. Acta Medica Transilvanica, 2012;2:159-162.
- 5. BakerbMT. Sevoflurane: are there differences in product? Anesth Analg, 2007; 1447-51.
- 6. O'Neil B, Hafiz MA, DeBeert DA. Corosion of Penelon Sevoflurane Vaporizer. Anaesthesia, 2007;62:421.
- 7. Gupta A, Ely J. Faulty sevoflurane vaporizer. Anaesthesia, 2007;62:421
- 8. Alfredo AVP, Solange ML, Deise MR, Maria IMR, Santiago OQ. A double-blind comparative study between generic Sevoflurane and Sevorane. Rev Bras Anesthesiolol, 2010;60:Campinas Sept./oct
- 9. A Ergolu, E Erturk, H Bostan. Sevofluran Anaesthesia in a patient with renal transplantation: Case Report and literature Reviw. The Journal of anesthesiology, 2006;13:1.
- 10. Jin Ha Park, Jae Hoon Leel, Dong Jin Joo, Ki Jun Song, Yu Seun Kim, and Bon-Nyeo Koo. Effect of sevoflurane on grafted kidney function in renal transplantation. Korean J Anesthesiol, 2012;62:529-535.
- 11. FDA Professional Drug Information:
- 12. RM Bermudez, SG Garcia, DP Surribas, et. al. Consensus Document. Recommandations on assessing proteinuria during the diagnosis and follow-up of cronic kidney disease. Nefrologia 2011;31:331-345.
- 13. Hines RL, Marschall KE. Stoeltings,s Anesthesia and co-existing disease. Renal Tubular Function and Integrity, 2012;Chapter 17 Renal Disease:336-337.